Patel, Jaimin http://orcid.org/0000-0002-6022-9881
Panicker, Nikhil http://orcid.org/0000-0003-1752-4284
Dawson, Valina L. http://orcid.org/0000-0002-2915-3970
Dawson, Ted M. http://orcid.org/0000-0002-6459-0893
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (NS38377, NS102035)
National Institute on Aging (AG059686)
JPB Foundation
Michael J. Fox Foundation for Parkinson's Research
RMS Foundation
Article History
Accepted: 20 October 2022
First Online: 15 November 2022
Declarations
:
: This work was supported by grants from the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NS38377, NS097049, and NS102035), and the JPB Foundation.
: Consulting: T.M.D has received personal compensation for consulting with Sun Pharma Advanced Research Company; T.M.D. is a consultant for Mitokinin; T.M.D. and V.L.D. are consultants to Inhibikase Therapeutics Inc.; T.M.D. serves on the Board of Directors and is compensated for his roles as a consultant and interim Chief Scientific Officer of Valted Seq Inc.; V.L.D. serves on the Board of Directors and is compensated for her role as interim Chief Executive Officer of Valted Seq Inc. T.M.D. was a paid consultant and advisory board member to DONG-A ST; T.M.D. and V.L.D. received personal compensation for consulting and serving on a scientific advisory board with Hopstem, Inc. These arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. Stock Ownership: T.M.D. owns stock options in American Gene Technologies International Inc.; T.M.D owns stock and stock options in Mitokinin; T.M.D. and V.L.D. own stock options in Inhibikase Therapeutics Inc.; T.M.D. and V.L.D. are founders of Valted, LLC and holds an ownership equity interest in the company. T.M.D. and V.L.D. are inventors of technology of Neuraly, Inc. that has optioned from Johns Hopkins University. T.M.D. and V.L.D. are founders of, and holds shares of stock options as well as equity in, Neuraly, Inc., which is now a subsidiary of D & D Pharmatech; T.M.D. and V.L.D. holds shares of stock options as well as equity in D & D Pharmatech; T.M.D. and V.L.D. are founders of and hold equity in Valted Seq Inc.; these arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. J.P. and N.P. have no conflicts of interest or disclosures.
: Not applicable.
: Not applicable.
: Not applicable.
: No original data or supplemental materials were generated in the process of writing this manuscript.
: Not applicable.
: JP reviewed the literature, conceptualized and developed the original draft of the manuscript, and participated in reviewing as well as editing the manuscript. NP participated in the literature searching and conceptualizing, reviewing, and editing the manuscript. TMD and VLD both participated in reviewing, editing, and conceptualizing the manuscript. All authors have read and approved the final version of the manuscript, and they agree to be accountable for the work.